

PATENT ASSIGNMENT

Electronic Version v1.1  
Stylesheet Version v1.1

SUBMISSION TYPE:	NEW ASSIGNMENT
NATURE OF CONVEYANCE:	RELEASE BY SECURED PARTY
CONVEYING PARTY DATA	
Name	Execution Date
CREDIT SUISSE AG	01/31/2011
RECEIVING PARTY DATA	
Name:	KING PHARMACEUTICALS, INC.
Street Address:	501 FIFTH STREET
City:	BRISTOL
State/Country:	TENNESSEE
Postal Code:	37620
PROPERTY NUMBERS Total: 27	
Property Type	Number
Patent Number:	5142039
Patent Number:	5057607
Patent Number:	5106475
Patent Number:	5077287
Patent Number:	5089610
Patent Number:	5142038
Patent Number:	5159073
Patent Number:	5116972
Patent Number:	5248493
Patent Number:	5239068
Patent Number:	5256807
Patent Number:	5225553
Patent Number:	5239069
Patent Number:	5352782
Patent Number:	5296615

501424751

PATENT  
REEL: 025735 FRAME: 0513

CH \$1080.00 5142039

Patent Number:	5374719
Patent Number:	5399686
Patent Number:	5550231
Patent Number:	5443833
Patent Number:	5453503
Patent Number:	5580977
Patent Number:	5578720
Patent Number:	RE38628
Application Number:	11927918
Application Number:	12455571
Patent Number:	5283329
Patent Number:	5169945

#### CORRESPONDENCE DATA

Fax Number: (202)778-6493

*Correspondence will be sent via US Mail when the fax attempt is unsuccessful.*

Phone: 202-662-6493

Email: kashton@cov.com

Correspondent Name: Covington & Burling LLP

Address Line 1: 1201 Pennsylvania Avenue, N.W.

Address Line 2: Attn: Patent Docketing

Address Line 4: Washington, DISTRICT OF COLUMBIA 20004-2401

ATTORNEY DOCKET NUMBER:	029459.00030
-------------------------	--------------

NAME OF SUBMITTER:	Andrea Reister
--------------------	----------------

#### Total Attachments: 5

source=King Pharmaceuticals Patent Release#page1.tif

source=King Pharmaceuticals Patent Release#page2.tif

source=King Pharmaceuticals Patent Release#page3.tif

source=King Pharmaceuticals Patent Release#page4.tif

source=King Pharmaceuticals Patent Release#page5.tif

## **Release of Security Interest in Patents**

**January 31, 2011**

**WHEREAS**, KING PHARMACEUTICALS, INC., a Tennessee corporation, as Borrower (the “Assignee”), certain of its subsidiaries, as Guarantors, and CREDIT SUISSE AG (“Credit Suisse”), in its capacity as Collateral Agent for the Secured Parties (as each term is defined in the GCA (as defined below)), entered into that certain Guarantee and Collateral Agreement (the “GCA”) dated as of May 11, 2010;

**WHEREAS**, pursuant to the GCA, Credit Suisse and the Assignee entered into that certain Patent Security Agreement dated May 11, 2010 and recorded with the United States Patent and Trademark Office on May 14, 2010 on Reel No. 024380, Frame No. 0645 (the “Patent Security Agreement”);

**WHEREAS**, under the Patent Security Agreement, the Assignee granted to Credit Suisse a security interest in certain Patent Collateral (as defined in the Patent Security Agreement), including those items set forth on Schedule 1 hereto (collectively, the “Released Patent Collateral”);

**WHEREAS**, the parties agree and acknowledge that the foregoing United States Patent and Trademark Office assignment record may list Credit Suisse AG in a capacity other than Collateral Agent, and that the security interest was granted to, and this release is correctly made by, Credit Suisse, as Collateral Agent; and

**WHEREAS**, Credit Suisse desires to release the security interest granted by the Assignee under the Patent Security Agreement in the Released Patent Collateral.


**NOW, THEREFORE**, for good and valuable consideration, the receipt and sufficiency of which are hereby acknowledged, Credit Suisse, as Collateral Agent for the Secured Parties, does hereby unconditionally, irrevocably and absolutely terminate, release, extinguish and forever discharge the security interest granted under the Patent Security Agreement in the Released Patent Collateral and hereby unconditionally, irrevocably and absolutely assigns, transfers and conveys to the Assignee, without any representation or warranty by, or recourse to, Credit Suisse, all right, title and interest of Credit Suisse in, to and under such Released Patent Collateral granted under the Patent Security Agreement. This Release of Security Interest in Patents shall be binding upon Credit Suisse’s legal representatives, assigns and successors, and upon the Secured Parties and their legal representatives, assigns and successors. Credit Suisse also hereby authorizes, and requests, the Director of the United States Patent and Trademark Office or his delegate to record this Release of Security Interest in Patents against the Released Patent Collateral.

*[signature page to follow]*

IN WITNESS WHEREOF, Credit Suisse has caused this Release of Security Interest in Patents to be duly executed by its officers thereunto duly authorized as of the day and year first above written.

CREDIT SUISSE AG, CAYMAN  
ISLANDS BRANCH

By:   
Name: **DOREEN BARR**  
Title: **DIRECTOR**

By:   
Name: **VIPUL DHADDA**  
Title: **ASSOCIATE**

*[signature page – King Pharmaceuticals, Inc. patent release]*

**Schedule 1**

**KING PHARMACEUTICALS, INC.**

**PATENTS AND PATENT APPLICATIONS**

<b>Internal Title</b>	<b>Filing #</b>	<b>Grant #</b>	<b>Type<sup>1</sup></b>	<b>Expiration</b>
Bicyclic Beta-Lactam Antibiotics	07/588,381	5,142,039	DIV	August 25, 2009
Enantiomerically Selective Biocatalyzed	07/591,586	5,057,607	CIP	June 8, 2010
Process For Preparing 4-Substituted Azetidinones	07/598,527	5,106,475	DIV	September 20, 2009
3-Thiazolylthio Carbacephem Antibacterial Agents	07/643,244	5,077,287	NP	January 18, 2011
Ring-Closure Method For 1-Carbacephalosporin Six-Membered Ring	07/691,257	5,089,610	NP	April 25, 2011
Process Of Enantiomeric Separation Of Carbacephem Intermediates	07/734,394	5,142,038	NP	July 23, 2011
Intermediates To 1-Carbacephalopriins and Process For Preparation Thereof	07/735,747	5,159,073	CNT	September 13, 2010
Ring-Closure Method For 1-Carbacephalosporin Six-Membered Ring	07/744,857	5,116,972	DIV	April 25, 2011
Pharmaceutical Composition	07/771,795	5,248,493	CNT	October 4, 2011
Bicyclic Beta-Lactam Antibiotics	07/871,376	5,239,068	DIV	August 24, 2010
Process and Intermediates For Chiral Epoxides	07/881,913	5,256,807	DIV	October 3, 2010
Intermediates To 1-Carbacephalopriins and Process For Preparation Thereof	07/889,221	5,225,553	DIV	September 13, 2010
Amino Protecting Group	07/918,196	5,239,069	DIV	August 24, 2010

<sup>1</sup> Within this chart, the following abbreviations are used with reference to the Type of Patent/ Application:

NP = Non-Provisional  
PSP = Provisional  
DIV = Divisional  
CIP = Continuation-in-Part

CNT = Continuation  
REI = Reissue  
DP = Design Patent

Process For Preparing Crystalline Beta-Lactam Monohydrate	071,552	5,352,782	NP	June 4, 2013
Process and Intermediates For Chiral Epoxides	08/012,109	5,296,615	DIV	March 22, 2011
Process For Converting Loracarbef Dihydrate To Loracarbef Monohydrate	08/071,550	5,374,719	NP	June 4, 2013
Loracarbef Isopropanolate and A Process For Converting Loracarbef Isopropanolate To Loracabef Monohydrate	08/072,204	5,399,686	NP	June 4, 2013
Lorabacarbef Hydrochloride C1-C3 Alcohol Solvates and Uses Thereof	08/077,305	5,550,231	NP	August 27, 2013
Pharmaceutical Compositions	08/082,804	5,443,833	CNT	June 25, 2013
Azetidinone Intermediates To Carbacephalosporins and Process	08/104,383	5,453,503	NP	August 9, 2013
Process For Preparing Loracarbef Monohydrate	08/396,948	5,580,977	NP	March 1, 2015
Lorabacarbef Hydrochloride C1 - C3 Alcohol Solvates and Uses Thereof	08/444,124	5,578,720	DIV	May 18, 2015
Pharmaceutical Compositions	08/916,578	RE38,628	REI	June 25, 2013
Thrombin Purification	11/927,918		CNT	May 26, 2025
Oxygen-Impervious Packaging and Methods for Storing Thyroid Hormone Pharmaceutical Compositions	12/455,571		CIP	06/3/2029
Amino Protecting Group	25,301	5,283,329	DIV	February 1, 2011
Amino Protecting Group	750,214	5,169,945	CNT	May 14, 2010

## PATENT LICENSES

<b>Name of Agreement</b>	<b>Parties Licensor/Licensee</b>	<b>Date of Agreement</b>	<b>Subject Matter</b>
Purchase Agreement	Ligand Pharmaceuticals Incorporated/ King Pharmaceuticals, Inc. and King Pharmaceuticals Research and Development, Inc.	September 6, 2006	Avinza
Assignment, Assumption and Consent Agreement	Elan Pharma International Limited and Elan Management Limited/ King Pharmaceuticals Inc. and King Pharmaceuticals Research and Development, Inc.	February 26, 2007	Avinza
License Agreement	Pain Therapeutics, Inc./  King Pharmaceuticals, Inc.	December 29, 2005	Remoxy
License Agreement	Mutual Pharmaceuticals Company Inc./  King Pharmaceuticals, Inc.	December 6, 2005	Skelaxin
Amended and Restated Asset Purchase Agreement	Elan Corporation, plc, Elan Pharma International Limited, Elan Pharmaceuticals, Inc./ King Pharmaceuticals, Inc., Jones Pharma Incorporated, and Monarch Pharmaceuticals, Inc.	May 19, 2003	Skelaxin
Product Acquisition and License Agreement	Aventis Pharma S.A./  King Pharmaceuticals, Inc.	December 30, 2002	Synercid